Steven A. Rosenberg, M.D., Ph.D.

Steven A. Rosenberg, M.D., Ph.D.
Chief
Senior Investigator
Head, Tumor Immunology Section

Dr. Rosenberg pioneered the development of effective immunotherapies and gene therapies for patients with advanced cancers. His studies of the adoptive transfer of genetically modified lymphocytes have resulted in the regression of metastatic cancer in patients with melanoma, sarcomas and lymphomas.

His current research is aimed at defining the host immune response of patients to their cancers. These studies emphasize the ability of human lymphocytes to recognize unique cancer antigens and the identification of anti-tumor T cell receptors that can be exploited to develop new cell transfer immunotherapies for the treatment of cancer patients.

As Chief, Dr. Rosenberg also oversees the Branch’s extensive clinical program aimed at translating scientific advances into effective immunotherapies for patients with cancer

Areas of Expertise
1) cancer immunotherapy 2) tumor-infiltrating lymphocytes 3) cancer antigens 4) T cell receptors 5) metastatic melanoma 6) gene therapy

Contact Info

Steven A. Rosenberg, M.D., Ph.D.
Center for Cancer Research
National Cancer Institute
Building 10 - Hatfield CRC, Room 3-3940
Bethesda, MD 20892-1201
Ph: 301-496-4164
SAR@nih.gov

Dr. Rosenberg has pioneered the development of immunotherapy that has resulted in the first effective immunotherapies for selected patients with advanced cancer. His studies of cell transfer immunotherapy have resulted in durable complete remissions in patients with metastatic melanoma. He has also pioneered the development of gene therapy and was the first to successfully insert foreign genes into humans. His recent studies of the adoptive transfer of genetically modified lymphocytes has resulted in the regression of metastatic cancer in patients with melanoma, sarcomas and lymphomas.

Scientific Focus Areas:
Cancer Biology, Clinical Research, Immunology
View Dr. Rosenberg's PubMed Summary.

Selected Key Publications

  1. Tran E, Robbins PF, Rosenberg SA
    Nat Immunol. 18(3): 255-262, 2017. [ Journal Article ]
  2. Tran E, Robbins PF, Lu YC, Prickett TD, Gartner JJ, Jia L, Pasetto A, Zheng Z, Ray S, Groh EM, Kriley IR, Rosenberg SA
    N Engl J Med. 375(23): 2255-2262, 2016. [ Journal Article ]
  3. Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS, Parkhurst MR, Yang JC, Rosenberg SA.
    Science. 344: 641-5, 2014. [ Journal Article ]
  4. Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, Lin JC, Teer JK, Cliften P, Tycksen E, Samuels Y, Rosenberg SA
    Nat Med. 19: 747-752, 2013. [ Journal Article ]
  5. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, Morton KE, Laurencot CM, Steinberg SM, White DE, Dudley ME
    Clin Cancer Res. 17: 4550-4557, 2011. [ Journal Article ]

Dr. Rosenberg is Chief of Surgery at the National Cancer Institute in Bethesda, Maryland and a Professor of Surgery at the Uniformed Services University of Health Sciences and the George Washington University School of Medicine and Health Sciences. He received his B.A. and M.D. degrees at Johns Hopkins University and a Ph.D. in Biophysics at Harvard University. After completing his residency training in surgery in 1974 at the Peter Bent Brigham Hospital in Boston, Massachusetts, Dr. Rosenberg became the Chief of Surgery at the NCI, NIH, a position he has held to the present time. Dr. Rosenberg developed the first effective immunotherapies and gene therapies for patients with advanced cancer. His studies of cell transfer immunotherapy have resulted in durable complete remissions in patients with metastatic melanoma. He was the first to successfully insert foreign genes into humans and his recent studies of the adoptive transfer of genetically modified lymphocytes has resulted in the regression of metastatic cancer in patients with melanoma, sarcomas and lymphomas.

Name Position
Mary Black Biologist
Ellen Bodurian R.N., B.S.N. Research Nurse
Eugene S. Bond Contractor
Colleen E. Buckley R.N. Research Nurse Specialist
Gal Cafri Ph.D. Postdoctoral Fellow (Visiting)
Xuemei (Sherry) Chen R.N. Research Nurse
Harshini Chinnasamy Biologist
Melissa A. Corbitt IT Specialist
David N. Danforth Jr., M.S., M.D. Staff Clinician
Drew Deniger Ph.D. Postdoctoral Fellow (CRTA)
Monica Epstein R.N., B.S.N., O.C.N. Research Nurse Specialist
Brittany L. Garr-Colon M.P.H., CCRP Protocol Coordinator (Contr.)
Stephanie L. Goff, M.D. Staff Clinician
Hyuni K. Halas Ph.D. Contractor
Vid Leko M.D. Clinical Fellow
Mary Link R.N. Research Nurse Specialist
Frank J. Lowery Ph.D. Research Fellow
Yong-Chen (William) Lu Ph.D. Staff Scientist
Parisa Malekzadeh M.D. Clinical Fellow
Deepti Jillella Marshall Patient Care Coordinator (Contr.)
Christine T. McGowan R.N. Research Nurse Specialist
Lori S. McIntyre R.N., B.S.N. Research Nurse Specialist
Lien T. Ngo Technical Laboratory Manager
Jennifer A. Pappas M.H.S. Regulatory Affairs Manager (Contr.)
Biman C. Paria Ph.D. Biologist
Sarah C. Ramirez R.N., B.S.N. Research Nurse Specialist
Satyajit Ray Ph.D. Biologist
Nicole Sellers Contractor
Richard M. Sherry, M.D. Staff Clinician
Margaret (Peggy) A. Shovlin R.N. Research Nurse
Donald E. White IT Specialist
Hui Xu Biologist
Rami Yoseph Ph.D. Postdoctoral Fellow (Visiting)
Jennifer V. Young R.N. Research Nurse
Nikolaos Zacharakis Ph.D. Research Fellow
Zhili Zheng Biologist

Clinical Trials

Research

Dr. Rosenberg has pioneered the development of immunotherapy that has resulted in the first effective immunotherapies for selected patients with advanced cancer. His studies of cell transfer immunotherapy have resulted in durable complete remissions in patients with metastatic melanoma. He has also pioneered the development of gene therapy and was the first to successfully insert foreign genes into humans. His recent studies of the adoptive transfer of genetically modified lymphocytes has resulted in the regression of metastatic cancer in patients with melanoma, sarcomas and lymphomas.

Scientific Focus Areas:
Cancer Biology, Clinical Research, Immunology

Publications

View Dr. Rosenberg's PubMed Summary.

Selected Key Publications

  1. Tran E, Robbins PF, Rosenberg SA
    Nat Immunol. 18(3): 255-262, 2017. [ Journal Article ]
  2. Tran E, Robbins PF, Lu YC, Prickett TD, Gartner JJ, Jia L, Pasetto A, Zheng Z, Ray S, Groh EM, Kriley IR, Rosenberg SA
    N Engl J Med. 375(23): 2255-2262, 2016. [ Journal Article ]
  3. Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS, Parkhurst MR, Yang JC, Rosenberg SA.
    Science. 344: 641-5, 2014. [ Journal Article ]
  4. Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, Lin JC, Teer JK, Cliften P, Tycksen E, Samuels Y, Rosenberg SA
    Nat Med. 19: 747-752, 2013. [ Journal Article ]
  5. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, Morton KE, Laurencot CM, Steinberg SM, White DE, Dudley ME
    Clin Cancer Res. 17: 4550-4557, 2011. [ Journal Article ]

Biography

Dr. Rosenberg is Chief of Surgery at the National Cancer Institute in Bethesda, Maryland and a Professor of Surgery at the Uniformed Services University of Health Sciences and the George Washington University School of Medicine and Health Sciences. He received his B.A. and M.D. degrees at Johns Hopkins University and a Ph.D. in Biophysics at Harvard University. After completing his residency training in surgery in 1974 at the Peter Bent Brigham Hospital in Boston, Massachusetts, Dr. Rosenberg became the Chief of Surgery at the NCI, NIH, a position he has held to the present time. Dr. Rosenberg developed the first effective immunotherapies and gene therapies for patients with advanced cancer. His studies of cell transfer immunotherapy have resulted in durable complete remissions in patients with metastatic melanoma. He was the first to successfully insert foreign genes into humans and his recent studies of the adoptive transfer of genetically modified lymphocytes has resulted in the regression of metastatic cancer in patients with melanoma, sarcomas and lymphomas.

Team

Name Position
Mary Black Biologist
Ellen Bodurian R.N., B.S.N. Research Nurse
Eugene S. Bond Contractor
Colleen E. Buckley R.N. Research Nurse Specialist
Gal Cafri Ph.D. Postdoctoral Fellow (Visiting)
Xuemei (Sherry) Chen R.N. Research Nurse
Harshini Chinnasamy Biologist
Melissa A. Corbitt IT Specialist
David N. Danforth Jr., M.S., M.D. Staff Clinician
Drew Deniger Ph.D. Postdoctoral Fellow (CRTA)
Monica Epstein R.N., B.S.N., O.C.N. Research Nurse Specialist
Brittany L. Garr-Colon M.P.H., CCRP Protocol Coordinator (Contr.)
Stephanie L. Goff, M.D. Staff Clinician
Hyuni K. Halas Ph.D. Contractor
Vid Leko M.D. Clinical Fellow
Mary Link R.N. Research Nurse Specialist
Frank J. Lowery Ph.D. Research Fellow
Yong-Chen (William) Lu Ph.D. Staff Scientist
Parisa Malekzadeh M.D. Clinical Fellow
Deepti Jillella Marshall Patient Care Coordinator (Contr.)
Christine T. McGowan R.N. Research Nurse Specialist
Lori S. McIntyre R.N., B.S.N. Research Nurse Specialist
Lien T. Ngo Technical Laboratory Manager
Jennifer A. Pappas M.H.S. Regulatory Affairs Manager (Contr.)
Biman C. Paria Ph.D. Biologist
Sarah C. Ramirez R.N., B.S.N. Research Nurse Specialist
Satyajit Ray Ph.D. Biologist
Nicole Sellers Contractor
Richard M. Sherry, M.D. Staff Clinician
Margaret (Peggy) A. Shovlin R.N. Research Nurse
Donald E. White IT Specialist
Hui Xu Biologist
Rami Yoseph Ph.D. Postdoctoral Fellow (Visiting)
Jennifer V. Young R.N. Research Nurse
Nikolaos Zacharakis Ph.D. Research Fellow
Zhili Zheng Biologist